Cervical screening: toward an equal risk/equal management approach, irrespective of HIV status

    loading  Checking for direct PDF access through Ovid


The introduction of human papillomavirus (HPV) testing has the potential to improve the accuracy of cervical cancer screening, but it has led to a multiplicity of possible protocols. So the decision to establish guidelines based on risk thresholds (benchmarks) to allow equal management for equal risk, irrespective of the screening test, is highly appropriate [1]. In the United States, for example, the benchmark that allows for a ‘routine’ recall after 3 years is a risk of biopsy-confirmed cervical high-grade squamous intraepithelial neoplasia or worse (bHSIL+) of 0.69%, based on the 3-year risk associated with a negative cytology. The benchmarks for 6–12-month return and for immediate colposcopy are 3-year risk of 8.8 and 14.4%, respectively [2].

Related Topics

    loading  Loading Related Articles